Rapid Dose Therapeutics (XCNQ:DOSE) ROCE % : 0.00% (As of Aug. 2024)

View and export this data going back to 2010. Start your Free Trial

What is Rapid Dose Therapeutics ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Rapid Dose Therapeutics's annualized ROCE % for the quarter that ended in Aug. 2024 was 0.00%.

Rapid Dose Therapeutics ROCE % Historical Data

The historical data trend for Rapid Dose Therapeutics's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rapid Dose Therapeutics ROCE % Chart

Rapid Dose Therapeutics Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Feb19

Feb20

Feb21

Feb22

Feb23

Feb24

ROCE %

Get a 7-Day Free Trial

-338.69

-839.90

-8,354.00

Rapid Dose Therapeutics Quarterly Data
	Nov19	Feb20	May20	Aug20	Nov20	Feb21	May21	Aug21	Nov21	Feb22	May22	Aug22	Nov22	Feb23	May23	Aug23	Nov23	Feb24	May24	Aug24
ROCE %	Get a 7-Day Free Trial															-	-	-	-	-

Rapid Dose Therapeutics ROCE % Calculation

Rapid Dose Therapeutics's annualized ROCE % for the fiscal year that ended in Feb. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Feb. 2024 )		(A: Feb. 2023 )		(A: Feb. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Feb. 2024 )		(A: Feb. 2023 )		(A: Feb. 2024 )
	=	-3.645	/	( ( (2.247 - 4.878)	+	(1.885 - 2.918) )	/ 2 )
	=	-3.645	/	( (-2.631	+	-1.033)	/ 2 )
	=	-3.645	/	-1.832
	=	198.96 %

Rapid Dose Therapeutics's ROCE % of for the quarter that ended in Aug. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Aug. 2024 )		(Q: May. 2024 )		(Q: Aug. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Aug. 2024 )		(Q: May. 2024 )		(Q: Aug. 2024 )
	=	-3.432	/	( ( (1.815 - 2.875)	+	(1.717 - 3.105) )	/ 2 )
	=	-3.432	/	( ( -1.06	+	-1.388 )	/ 2 )
	=	-3.432	/	-1.224
	=	0 %

(1) Note: The EBIT data used here is four times the quarterly (Aug. 2024) EBIT data.

Rapid Dose Therapeutics (XCNQ:DOSE) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Rapid Dose Therapeutics ROCE % Related Terms

Thank you for viewing the detailed overview of Rapid Dose Therapeutics's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Rapid Dose Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rapid Dose Therapeutics Corp (XCNQ:DOSE) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

RDTCF:USA

Address

1121 Walkers Line, Unit 3, Burlington, ON, CAN, L7N 2G4

Website

https://www.rapid-dose.com

Rapid Dose Therapeutics Corp is a Canadian biotechnology company revolutionizing drug delivery through innovation. The company's flagship product QuickStrip is a thin, orally dissolvable film, that can be infused with an infinite list of active ingredients (nutraceuticals, pharmaceuticals, vaccines, and cannabis) that are delivered quickly into the bloodstream resulting in rapid onset of the active ingredient.

Executives

Mark Upsdell	Director
Brian Howlett	Director

Rapid Dose Therapeutics Headlines

No Headlines